Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis.
about
Tempering allorecognition to induce transplant tolerance with chemically modified apoptotic donor cellsAntigen-based immunotherapy for autoimmune disease: current statusAntigen-specific tolerance in immunotherapy of Th2-associated allergic diseases.Restoring the balance: immunotherapeutic combinations for autoimmune diseaseAntigen-specific suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor: structure optimization and pharmacokineticsMolecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy.Therapeutic blockade of T-cell antigen receptor signal transduction and costimulation in autoimmune diseaseImmunotherapy in food allergy.'Multi-epitope-targeted' immune-specific therapy for a multiple sclerosis-like disease via engineered multi-epitope protein is superior to peptidesEthylenecarbodiimide-treated splenocytes carrying male CD4 epitopes confer histocompatibility Y chromosome antigen transplant protection by inhibiting CD154 upregulation.Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy.Preclinical development and first-in-human study of ATX-MS-1467 for immunotherapy of MSStructure, size, and solubility of antigen arrays determines efficacy in experimental autoimmune encephalomyelitis.Codelivery of antigen and an immune cell adhesion inhibitor is necessary for efficacy of soluble antigen arrays in experimental autoimmune encephalomyelitisAntigen-specific blocking of CD4-specific immunological synapse formation using BPI and current therapies for autoimmune diseases.Multi-peptide coupled-cell tolerance ameliorates ongoing relapsing EAE associated with multiple pathogenic autoreactivities.Multimerized T cell epitopes protect from experimental autoimmune diabetes by inducing dominant tolerance.Mast Cells are Important Modifiers of Autoimmune Disease: With so Much Evidence, Why is There Still Controversy?Mechanisms of immunological tolerance in central nervous system inflammatory demyelination.Immune modulating peptides for the treatment and suppression of multiple sclerosis.Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9-23 epitope and involves functional epitope spreading.Targeting the TCR: T-cell receptor and peptide-specific tolerance-based strategies for restoring self-tolerance in CNS autoimmune disease.Antigen-specific therapies in multiple sclerosis.Tolerance induction using nanoparticles bearing HY peptides in bone marrow transplantation.Current and future immunomodulation strategies to restore tolerance in autoimmune diseases.Vaccinelike and prophylactic treatments of EAE with novel I-domain antigen conjugates (IDAC): targeting multiple antigenic peptides to APCMicroparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis.Biomaterial Strategies for Immunomodulation.Prophylactic and therapeutic suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor.Immune Tolerance for Autoimmune Disease and Cell TransplantationBiodegradable antigen-associated PLG nanoparticles tolerize Th2-mediated allergic airway inflammation pre- and postsensitization.Peptide-based immunotherapy of experimental autoimmune encephalomyelitis without anaphylaxis.L.E.A.P.S. heteroconjugate is able to prevent and treat experimental autoimmune myocarditis by altering trafficking of autoaggressive cells to the heart.Prospects for antigen-specific tolerance based therapies for the treatment of multiple sclerosisAntigen-specific gene therapy after immunisation reduces the severity of collagen-induced arthritis.Emerging immunopharmacological targets in multiple sclerosis.A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease.Tolerance strategies employing antigen-coupled apoptotic cells and carboxylated PLG nanoparticles for the treatment of type 1 diabetes.The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment.In situ expansion of T cells that recognize distinct self-antigens sustains autoimmunity in the CNS.
P2860
Q26851647-F5FB3E42-D6AB-485C-A97D-17A15C26ECE5Q26852915-33D9D0BA-6DCA-45EC-BCA9-3194FE9F0DF4Q27687250-641B9AB8-81D1-4731-B4C5-1A92DBFCD1F2Q33555986-B71A9DBF-7D11-48EA-A8F1-6B2412891124Q33714913-C3ED9878-03B3-4C67-B629-533F1A16001CQ33753720-620D7EEB-0E36-466C-90E1-14D098059C03Q33785953-C425577C-DE09-4D26-8F4D-910A9620DA44Q33899364-002BDF7F-D175-440E-AF29-A15EE6401061Q34091080-4AB24274-13CE-4570-B32B-AA54468919D5Q34103866-EF93161E-C3C1-47E3-924F-DC2398108C3DQ34205503-1D5E007C-3E69-4364-8642-250FEFE0231EQ35179832-9A90E89F-A5D9-44A9-AD50-7E2C7E503365Q35318199-ED2CD79E-4142-4CDF-B80D-4FB8D404A630Q35571156-5947D051-CD90-45EA-93FC-7EB23AFD56E8Q35637379-9CF12346-B3F4-46F6-BCF1-0A52A3CDB2BDQ35792672-AFBD2E70-1C23-4219-BBF4-44F41061AF30Q35839611-C33E8DE3-FF11-4B1C-9DF6-60FF09F7E56AQ36013705-5C7FACB8-B4B3-4AEB-A331-9DE937422ED9Q36095922-BA24EC45-D36E-4D05-9FD5-1E16B7C86F6AQ36151968-A136B659-0925-4A82-A3BC-51E5B29D0B7FQ36209928-62FF6DF1-7E54-4EA2-9D93-C3F4C78B7B57Q36327367-CB9A945D-0852-4C99-AF9C-BF875041C23FQ36327373-A73F1066-4F5F-469C-A4DA-D8EB0F65DEF2Q36327666-9EDE74D6-2B87-4059-BC9C-9563A6E8DB58Q36506677-07E54252-0B7F-463D-9A8E-E7C8455A01B4Q36518182-43562842-F2F0-498D-8CD1-B35A644EE99CQ36661068-FA3BFA96-DD3C-42F2-92E4-0D0801EAC5AEQ36703124-BC7E3C3D-8782-4016-862A-7194322A1D96Q37002699-F9BA8F95-43F6-45A7-8A94-03AD5B2D3F5EQ37099107-1AC528FA-6D8D-4066-92FF-570EDAE9E9B2Q37173058-4C690EC1-A1A7-45C6-BC1D-74476C1F40CBQ37235161-473847C9-CB06-4CC8-B95C-C5FAEA62DE0DQ37277258-FE9BA003-414E-47D1-9324-4FB9B3C09E53Q37364480-07456E65-B8DB-4E75-A26A-97FBC07D5851Q37382486-7051EC3F-FEDA-4E9D-8BA1-DB03EB937983Q37559970-6225AD75-DC3F-477C-A22A-7DA7EF838292Q37708089-D9F0C745-7815-4512-A686-16ED57B291C5Q38117283-D2A9B3C9-10D9-4E26-80A5-F4ECADA28520Q38186206-2CC8A836-4181-456D-9E6D-E4182DBAE8B7Q38438865-1C211DA8-33B0-440F-AA5B-D6741715B727
P2860
Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Differential induction of IgE- ...... autoimmune encephalomyelitis.
@ast
Differential induction of IgE- ...... autoimmune encephalomyelitis.
@en
type
label
Differential induction of IgE- ...... autoimmune encephalomyelitis.
@ast
Differential induction of IgE- ...... autoimmune encephalomyelitis.
@en
prefLabel
Differential induction of IgE- ...... autoimmune encephalomyelitis.
@ast
Differential induction of IgE- ...... autoimmune encephalomyelitis.
@en
P2093
P2860
P356
P1476
Differential induction of IgE- ...... f autoimmune encephalomyelitis
@en
P2093
Cassandra E Smith
Jack L Strominger
Stephen D Miller
P2860
P304
P356
10.1073/PNAS.0504131102
P407
P50
P577
2005-06-27T00:00:00Z